FLT3 and acute myeloid leukemia: Notably, IHCH9033 treatment significantly reduced the portion of hCD45+ and/or hCD45+hCD34+ in PB, BM and spleen in a primary FLT3-ITD AML PDX model, whereas quizartinib administration had minimal impact but significantly inhibited FLT3-ITD MV-4-11 xenograft tumors under the same treatment conditions.